Richard Oh

1.4k total citations
20 papers, 976 citations indexed

About

Richard Oh is a scholar working on Endocrinology, Diabetes and Metabolism, Psychiatry and Mental health and Surgery. According to data from OpenAlex, Richard Oh has authored 20 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Psychiatry and Mental health and 3 papers in Surgery. Recurrent topics in Richard Oh's work include Diabetes Treatment and Management (13 papers), Diabetes Management and Research (5 papers) and Bipolar Disorder and Treatment (4 papers). Richard Oh is often cited by papers focused on Diabetes Treatment and Management (13 papers), Diabetes Management and Research (5 papers) and Bipolar Disorder and Treatment (4 papers). Richard Oh collaborates with scholars based in United States, Australia and United Kingdom. Richard Oh's co-authors include Kenneth W. Mahaffey, Bruce Neal, Feihu Wang, Hao Su, Zongyuan Wang, Vlado Perkovic, Honggang Cui, Dongqing Xu, Fengyi Wan and Wenbing Dai and has published in prestigious journals such as Journal of the American College of Cardiology, Biomaterials and Diabetes.

In The Last Decade

Richard Oh

20 papers receiving 963 citations

Peers

Richard Oh

EDM

SURGE

IMMUN

Wen Guo China

Ta-Jen Wu Taiwan

Zhijia Wang China

Shihao Xu China

Yujie Jiang China

Simona Eliza Giuşcă Romania

Yuhan Qin China

Bingbing Zha China

Norihisa Nishimura Japan

Wen Guo China

Richard Oh

253 ×0.6

EDM

275 ×0.9

125 ×0.6

136 ×0.7

SURGE

180 ×0.9

IMMUN

Citations per year, relative to Richard Oh Richard Oh (= 1×) peers Wen Guo

Countries citing papers authored by Richard Oh

Since Specialization

Citations

This map shows the geographic impact of Richard Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Oh more than expected).

Fields of papers citing papers by Richard Oh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Oh. The network helps show where Richard Oh may publish in the future.

Co-authorship network of co-authors of Richard Oh

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Oh. A scholar is included among the top collaborators of Richard Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Oh. Richard Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Feihu, Hao Su, Dongqing Xu, et al.. (2021). Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. Biomaterials. 279. 121182–121182. 37 indexed citations

Oh, Richard, et al.. (2021). Edible Strip of Petai Peel (Parkia speciosa Hassk) as an Innovation for the Treatment of Diabetes Mellitus. Advances in Social Science, Education and Humanities Research. 1 indexed citations

Wang, Feihu, Dongqing Xu, Hao Su, et al.. (2020). Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy. Science Advances. 6(18). eaaz8985–eaaz8985. 129 indexed citations

Weir, Matthew R., April Slee, Tao Sun, et al.. (2020). Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. Clinical Kidney Journal. 14(5). 1396–1402. 19 indexed citations

Wang, Feihu, Hao Su, Dongqing Xu, et al.. (2020). Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. Nature Biomedical Engineering. 4(11). 1090–1101. 261 indexed citations

Li, Jingwei, Bruce Neal, Vlado Perkovic, et al.. (2020). Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney International. 98(3). 769–777. 92 indexed citations

Januzzi, James L., Jingwei Li, Wayne Shaw, et al.. (2020). Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide. Journal of the American College of Cardiology. 76(18). 2076–2085. 53 indexed citations

Jardine, Meg, Zien Zhou, Hiddo J.L. Heerspink, et al.. (2020). SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS. Kidney International Reports. 5(3). S67–S67. 1 indexed citations

Arnott, Clare, Brendon L. Neuen, Gian Luca Di Tanna, et al.. (2020). The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obesity and Metabolism. 22(10). 1753–1766. 34 indexed citations

10.

Bakris, George L., Meg Jardine, Zien Zhou, et al.. (2020). Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis. Journal of the American Society of Nephrology. 31(10S). 328–328. 1 indexed citations

11.

Zhou, Zien, Meg Jardine, Vlado Perkovic, et al.. (2019). Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. 62(10). 1854–1867. 59 indexed citations

12.

Neuen, Brendon L., Toshiaki Ohkuma, Bruce Neal, et al.. (2019). Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. Journal of the American Society of Nephrology. 30(11). 2229–2242. 101 indexed citations

13.

Mahaffey, K. W., Jiapeng Li, Sunil V. Badve, et al.. (2019). The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme. Diabetologia. 62. 1 indexed citations

14.

Li, Jingwei, Sunil V. Badve, Zien Zhou, et al.. (2019). The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. The Lancet Rheumatology. 1(4). e220–e228. 47 indexed citations

15.

Li, Jingwei, Sunil V. Badve, Zien Zhou, et al.. (2019). 1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program. Diabetes. 68(Supplement_1). 1 indexed citations

16.

Zhou, Zien, Richard I. Lindley, Karin Rådholm, et al.. (2018). Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke. 50(2). 396–404. 53 indexed citations

17.

Finkle, John K., Norman Stockbridge, Kaori Shinagawa, et al.. (2015). Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms. Therapeutic Innovation & Regulatory Science. 49(4). 511–513. 1 indexed citations

18.

White, William B., Stuart Kupfer, Steven Nissen, et al.. (2014). CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND RECENT ACUTE CORONARY SYNDROMES FROM THE EXAMINE TRIAL. Journal of the American College of Cardiology. 63(12). A116–A116. 6 indexed citations

19.

Zannad, Faı̈ez, Christopher P. Cannon, William C. Cushman, et al.. (2014). ALOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES AFTER ACUTE CORONARY SYNDROMES: HEART FAILURE OUTCOMES AND CARDIOVASCULAR SAFETY IN HEART FAILURE PATIENTS. Journal of the American College of Cardiology. 63(12). A117–A117. 12 indexed citations

20.

Oh, Richard. (2005). Practical Applications of Fish Oil ( -3 Fatty Acids) in Primary Care. The Journal of the American Board of Family Medicine. 18(1). 28–36. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact